Journal article
Facile synthesis of lactoferrin conjugated ultra small large pore silica nanoparticles for the treatment of glioblastoma
TI Janjua, A Ahmed-Cox, AK Meka, FM Mansfeld, H Forgham, RMC Ignacio, Y Cao, JA McCarroll, R Mazzieri, M Kavallaris, A Popat
Nanoscale | ROYAL SOC CHEMISTRY | Published : 2021
DOI: 10.1039/d1nr03553c
Abstract
The blood brain barrier (BBB) and blood tumour barrier (BTB) remain a major roadblock for delivering therapies to treat brain cancer. Amongst brain cancers, glioblastoma (GBM) is notoriously difficult to treat due to the challenge of delivering chemotherapeutic drugs across the BBB and into the tumour microenvironment. Consequently, GBM has high rates of tumour recurrence. Currently, limited numbers of chemotherapies are available that can cross the BBB to treat GBM. Nanomedicine is an attractive solution for treating GBM as it can augment drug penetration across the BBB and into the heterogeneous tumour site. However, very few nanomedicines exist that can easily overcome both the BBB and BT..
View full abstractGrants
Awarded by Australian Research Council
Funding Acknowledgements
We acknowledge the School of Pharmacy, University of Queensland for the research facilities. We thank the Australian Microscopy and Microanalysis Research Facility at the Centre for Microscopy and Microanalysis, The University of Queensland. TIJ and Y.C are thankful for the financial support from the University of Queensland Graduate School Scholarship (UQGSS). AA-C acknowledges support from the Scientia PhD Scholarship Scheme (RSRE9000, UNSW Sydney), the Josee Hilton Excellence Award and Children's Cancer Institute Postgraduate Top-up Scholarship. A.P. acknowledges financial support from National Health and Medical Research Council for the Early Career and Career Development Fellowships. R. M. is thankful to the Cure Brain Cancer Foundation for the Innovation Grant (21471) and to the Children Hospital Foundation for the Accelerator grant. MK acknowledges financial support from National Health and Medical Research (Program Grant APP1091261 and Principal Research Fellowship APP1119152), Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology (CE140100036), and Cancer Institute New South Wales (2019/TPG2037). JM acknowledges financial support from Cancer Australia/Kids Cancer Project (APP1184840) and the Mark Hughes Foundation for the innovation grant (MHF1461). MK, JM, HF, FMM and AA-C would like to thank the Biomedical Imaging Facility at the Mark Wainwright Analytical Centre, UNSW Sydney, for their support and resources involved in this work.